ConductScience.org, home
Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)
API referenceFor AI assistants

Trial · NCT02542293

Participant flow20

How many started, completed or left each group, period by period.

1 to 20 of 20

Download this page as JSON
PeriodMilestoneGroupParticipantsUnits counted
Overall StudySTARTEDAll Participants: Durvalumab + Tremelimumab474
Overall StudySTARTEDAll Participants: SoC Chemotherapy479
Overall StudyRandomized in Global CohortAll Participants: Durvalumab + Tremelimumab410
Overall StudyRandomized in Global CohortAll Participants: SoC Chemotherapy413
Overall StudyReceived Treatment in Global CohortAll Participants: Durvalumab + Tremelimumab410
Overall StudyReceived Treatment in Global CohortAll Participants: SoC Chemotherapy399
Overall StudyRandomized in China CohortAll Participants: Durvalumab + Tremelimumab78
Overall StudyRandomized in China CohortAll Participants: SoC Chemotherapy82
Overall StudyReceived Treatment in China CohortAll Participants: Durvalumab + Tremelimumab77
Overall StudyReceived Treatment in China CohortAll Participants: SoC Chemotherapy78
Overall StudyIncluded in Both Cohorts (Global and China)All Participants: Durvalumab + Tremelimumab14
Overall StudyIncluded in Both Cohorts (Global and China)All Participants: SoC Chemotherapy16
Overall StudyOngoing in Study at DCO for Final Analysis in Global CohortAll Participants: Durvalumab + Tremelimumab75
Overall StudyOngoing in Study at DCO for Final Analysis in Global CohortAll Participants: SoC Chemotherapy67
Overall StudyOngoing in Study at DCO for Final Analysis in China CohortAll Participants: Durvalumab + Tremelimumab27
Overall StudyOngoing in Study at DCO for Final Analysis in China CohortAll Participants: SoC Chemotherapy18
Overall StudyCOMPLETEDAll Participants: Durvalumab + Tremelimumab99
Overall StudyCOMPLETEDAll Participants: SoC Chemotherapy83
Overall StudyNOT COMPLETEDAll Participants: Durvalumab + Tremelimumab375
Overall StudyNOT COMPLETEDAll Participants: SoC Chemotherapy396

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02542293/flow

API referenceFor AI assistants